Similarly, the DERMA multicentre trials enrolled 895 patients with MAGEA3+ stage III melanoma and reported no differences in DFS between MAGE-A3 + AS15 vaccinated patients (11.0 months) and placebo controls (11.2 months) [40]. Here, MAGEA3 is linked to melanoma.